2026年3月最新《新锐期刊分区表》数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
体验更多LetPub AI科研工具 >> | |
| 近期推荐： | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 新 聚合物期刊JPM征稿｜IF持续上升 + APC折扣 | 热 Springer Nature特刊征稿 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | LANCET ONCOLOGY LANCET ONCOL （此期刊被最新的JCR期刊SCIE收录） LetPub评分 9.8
51人评分
我要评分
声誉 10.0 影响力 9.7 速度 9.3 | |||||||||||||||||||||
| 期刊ISSN | 1470-2045 | 安装APP，查看期刊最新消息
| ||||||||||||||||||||
| E-ISSN | 1474-5488 | |||||||||||||||||||||
| 2024-2025最新影响因子 （数据来源于搜索引擎） | 35.9 点击查看影响因子趋势图 | |||||||||||||||||||||
| 实时影响因子 | 截止2026年5月06日：33.23 | |||||||||||||||||||||
| 2024-2025自引率 | 1.7%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年影响因子 | 42 | |||||||||||||||||||||
| JCI期刊引文指标 | 8.62 | |||||||||||||||||||||
| h-index | 274 | |||||||||||||||||||||
| CiteScore （ 2025年最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | http://www.thelancet.com/journals/lanonc/issue/current | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/THELANCETONCOLOGY | |||||||||||||||||||||
| 该期刊中国学者近期发文 - New | Fuzuloparib plus apatinib in BRCAmutated breast cancer: balancing efficacy and accessibility in regional China Author: Qiu, Ziran; Jin, Na Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e125-e125. DOI: 10.1016/S1470-2045(25)00752-1 Fuzuloparib plus apatinib in BRCA- mutated breast cancer: balancing efficacy and accessibility in regional China Author: Liu, Jieqiong; Liu, Yaxin; Song, Erwei; Li, Huiping Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e126-e126. DOI: Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised double-blind, phase 3 study Author: Dummer, Reinhard; Guo, Jun; Luke, Jason J.; Carlino, Matteo S.; Schadendorf, Dirk; Khattak, Muhammad A.; Hauschild, Axel; Ascierto, Paolo A.; Chen, Yu; Shin, Sang Joon; Rutkowski, Piotr; Luo, Zhiguo; Chen, Jing; Rivalland, Gareth; Coetzee, Corlia; Ribas, Antoni; Mujika, Karmele; Markel, Gal; Villarroel, Rodrigo U.; Dizdar, Omer; Caglevic, Christian; Grebennik, Dmitri; Donovan, Kevin; Krepler, Clemens; Long, Georgina, V Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. 327-339. DOI: 10.1016/S1470-2045(25)00709-0 Standardising MET amplification testing: limitations of the GCN ≥6 criterion Reply Author: Wu, Yi-Long; Yao, Yu; Zhang, Pei-Long; Shi, He-Peng Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e128-e128. DOI: | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足LANCET ONCOLOGY的语言要求，还能让LANCET ONCOLOGY编辑和审稿人得到更好的审稿体验，让稿件最大限度地被LANCET ONCOLOGY编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710 | |||||||||||||||||||||
| 出版商 | Lancet Publishing Group | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||
| 出版年份 | 2000 | |||||||||||||||||||||
| 年文章数 | 168点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 14.58% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 83.33% | |||||||||||||||||||||
| WOS期刊JCR分区 （ 2024-2025年最新版） | WOS分区等级：1区
| |||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
  | ||||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1470-2045%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 一般,3-8周 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 极难 | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在LANCET ONCOLOGY顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Fuzuloparib plus apatinib in BRCAmutated breast cancer: balancing efficacy and accessibility in regional China Author: Qiu, Ziran; Jin, Na Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e125-e125. DOI: 10.1016/S1470-2045(25)00752-1 PubMed DOI |
| 2. | Fuzuloparib plus apatinib in BRCA- mutated breast cancer: balancing efficacy and accessibility in regional China Author: Liu, Jieqiong; Liu, Yaxin; Song, Erwei; Li, Huiping Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e126-e126. DOI: PubMed |
| 3. | Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised double-blind, phase 3 study Author: Dummer, Reinhard; Guo, Jun; Luke, Jason J.; Carlino, Matteo S.; Schadendorf, Dirk; Khattak, Muhammad A.; Hauschild, Axel; Ascierto, Paolo A.; Chen, Yu; Shin, Sang Joon; Rutkowski, Piotr; Luo, Zhiguo; Chen, Jing; Rivalland, Gareth; Coetzee, Corlia; Ribas, Antoni; Mujika, Karmele; Markel, Gal; Villarroel, Rodrigo U.; Dizdar, Omer; Caglevic, Christian; Grebennik, Dmitri; Donovan, Kevin; Krepler, Clemens; Long, Georgina, V Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. 327-339. DOI: 10.1016/S1470-2045(25)00709-0 PubMed DOI |
| 4. | Standardising MET amplification testing: limitations of the GCN ≥6 criterion Reply Author: Wu, Yi-Long; Yao, Yu; Zhang, Pei-Long; Shi, He-Peng Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e128-e128. DOI: PubMed |
| 5. | Standardising MET amplification testing: limitations of the GCN ≥6 criterion Author: Liu, Yuxin; Zhang, Dingdan; Tian, Shaodan Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e127-e127. DOI: 10.1016/S1470-2045(25)00758-2 PubMed DOI |
| 6. | International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression: recommendations for definitions, reporting items, and study endpoints for clinical trials and audits Author: Wong, Henry C. Y.; Choi, J. Isabelle; Marta, Gustavo Nader; Lee, Shing Fung; Chan, Adrian Wai; Santos, Monica D'alma Costa; Leung, Sheona; Wong, Edmond; Chan, Stephanie; Hircock, Caroline; Raman, Srinivas; Oldenburger, Eva; Simone Ii, Charles B.; Dearnaley, David; Maranzano, Ernesto; Chow, Edward; Rades, Dirk; Hoskin, Peter Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 2, pp. e111-e122. DOI: 10.1016/S1470-2045(25)00602-3 PubMed DOI |
| 7. | Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial Author: Zhang, Liang; Zhang, Xiqin; Wu, Lin; Xing, Wenqun; Liu, Chunling; Zhang, Peng; Chen, Kai; Shi, Jianhua; Xu, Shidong; Zhang, Xiaodong; Dong, Xiaorong; Fang, Haohui; Yu, Xinmin; Gao, Yang; Li, Gaofeng; Chen, Zhenming; Fan, Shaonan; Zhang, Xiaoqing; Cheng, Ying Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 2, pp. 159-168. DOI: 10.1016/S1470-2045(25)00643-6 PubMed DOI |
| 8. | Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial Author: Einsele, Hermann; San-Miguel, Jesus; Dhakal, Binod; Touzeau, Cyrille; Leleu, Xavier; Donk, Niels Wcj Van De; Sidana, Surbhi; Oriol, Albert; Cohen, Yael C.; Harrison, Simon J.; Mateos, Maria-Victoria; Martinez-Lopez, Joaquin; Corradini, Paolo; Karlin, Lionel; Chen, Diana; Li, Quanlin; Yeh, Tzu-min; Li, Katherine; Plaks, Vicki; Slaughter, Ana; Lonardi, Carolina; Benachour, Nina; Ghosh, Arnab; Vogel, Martin; Schecter, Jordan M.; Lendvai, Nikoletta; Koneru, Mythili; Patel, Nitin; Florendo, Erika; Ho, Phoebe Joy; Popat, Rakesh Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 2, pp. 254-268. DOI: 10.1016/S1470-2045(25)00653-9 PubMed DOI |
| 9. | Evaluation of progression-free status at 24 months as a surrogate endpoint for overall survival in patients with human papillomavirus-positive oropharyngeal cancer: a retrospective cohort study Author: Cao, Caineng; Sherman, Eric J.; Riaz, Nadeem; McBride, Sean M.; Yu, Yao; Shamseddine, Achraf; Wong, Winston; Dunn, Lara A.; Ho, Alan L.; Wong, Richard J.; Lee, Nancy Y Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 2, pp. 191-200. DOI: PubMed |
| 10. | Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial Author: Zhou, Jian; Bai, Li; Luo, Jia; Bai, Yuxian; Pan, Yaozhen; Yang, Xinrong; Gao, Yufeng; Shi, Rongshu; Zhang, Wenhua; Zheng, Jinfang; Hua, Xiangdong; Xu, Aibing; Hu, Sheng; Zhang, Feng; Yang, Xiaojun; Da, Mingxu; Wang, Rui; Ma, Jie; Jia, Weidong; Quan, Dongmei; Peng, Chuang; Yang, Wei; Yin, Guowen; Qi, Yue; Zhang, Guifang; Du, Xilin; Mao, Xiaorong; Meng, Zhiqiang; Jiao, Shunchang; Fan, Jia Journal: LANCET ONCOLOGY. 2025; Vol. 26, Issue 6, pp. 719-731. DOI: 10.1016/S1470-2045(25)00190-1 PubMed DOI |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共42条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
